494772-02-0

Basic information

• Product Name: 5-bromo-2-(cyclopropylmethoxy)pyridine
• Synonyms: 5-bromo-2-(cyclopropylmethoxy)pyridine
• CAS NO: 494772-02-0
• Molecular Formula: C9H10BrNO
• Molecular Weight: 228.088
• Mol File: 494772-02-0.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 5-bromo-2-(cyclopropylmethoxy)pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-bromo-2-(cyclopropylmethoxy)pyridine(494772-02-0)
• EPA Substance Registry System: 5-bromo-2-(cyclopropylmethoxy)pyridine(494772-02-0)

Safety Data

• Hazardous Substances Data: 494772-02-0(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
5-bromo-2-(cyclopropylmethoxy)pyridine is used as a key intermediate in organic synthesis for the creation of complex organic molecules. Its cyclopropyl group serves as a valuable synthetic handle, allowing for further functionalization and the development of a diverse range of chemical products.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 5-bromo-2-(cyclopropylmethoxy)pyridine is employed as a building block for the development of new drugs. Its unique structure and reactivity make it a promising candidate for the synthesis of bioactive compounds with potential therapeutic applications.
Used in Agrochemical Development:
5-bromo-2-(cyclopropylmethoxy)pyridine also has potential applications in the agrochemical sector, where it can be used as a starting material for the synthesis of novel agrochemicals with improved efficacy and selectivity.
Overall, 5-bromo-2-(cyclopropylmethoxy)pyridine is a versatile chemical compound with a wide range of applications in various industries, including organic synthesis, pharmaceutical research, and agrochemical development, due to its unique structure, reactivity, and synthetic potential.

Upstream product

• 624-28-2 2,5-dibromopyridine 
• 2516-33-8 Cyclopropylmethanol 
• 766-11-0 5-bromo-2-fluoropyridine 

Downstream Products

• 1224719-40-7 6-(2-cyclopropylmethoxy)pyridin-3-ol 
• 1344684-96-3 2-(cyclopropylmethoxy)-5-(methoxymethoxy)pyridine-4-carboxylic acid 
• 1443668-87-8 (S)-N-(1-(4-(1-(6-(cyclopropylmethoxy)pyridin-3-yl)azetidin-3-yloxy)phenyl)ethyl)-acetamide 
• 947191-69-7 2-(cyclopropylmethoxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine 

Relevant articles and documents

INHIBITORS OF TRPC6

The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts therefore, wherein R1 to R6, A, U, V, W, X, Y, and Z are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

AZETIDINE COMPOUNDS AS GRP119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS

The present disclosure relates to azetidine compounds. The azetidine compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The present disclosure furthermore relates to the use of azetidine compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

SUBSTITUTED FUSED HETEROCYCLES AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS

The present invention relates to substituted fused heterocyclic compounds. The substituted fused heterocyclic compounds are GPR1 19 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of substituted fused heterocyclic compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

ISOINDOLINONE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS

The present invention relates to isoindolinone compounds. The isoindolinone compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the u

SUBSTITUTED INDANONE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS

The present invention relates to indanone compounds. The indanone compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of inda

PYRROLIDINONE DERIVATIVES AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS

The present invention relates to pyrrolidinone derivatives. The pyrrolidinone derivatives are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to t

PYRROLIDINONE DERIVATIVES AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS

The present invention relates to pyrrolidinone derivatives of formula (I). The pyrrolidinone derivatives of formula (I) are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of pyrrolidinone derivatives as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

Pyrrolidine derivatives, pharmaceutical compositions and uses thereof

The invention relates to new pyrrolidine derivatives of the formula to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

The invention relates to new pyrrolidine derivatives of the formula (I), to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

AZETIDINE DERIVATIVES

Azetidine derivatives of which the following is exemplary and their use in the treatment of obesity, diabetes or dyslipidemia.